NICE Guidance October 2021
There is one guideline and one technology appraisal published in October 2021 by the National Institute for Clinical Excellence which has impact upon primary care.
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia technology appraisal has been published. This treatment is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults only if:
- there is a history of any of the following cardiovascular events:
- acute coronary syndrome (such as myocardial infarction or unstable angina needing hospital admission)
- coronary or other arterial revascularisation procedures
- coronary heart disease
- ischaemic stroke or
- peripheral arterial disease, and
- low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is:
- maximum tolerated statins with or without other lipid-lowering therapies or,
- other lipid-lowering therapies when statins are not tolerated or are contraindicated, and
- the company provides inclisiran according to the commercial arrangement.
It would be expected that treatment would be commenced and supervised by a clinician with a special interest however there is a unique funding arrangement in place that includes a new section in the Drug Tariff (DT) that will encourage use in primary care.
The looked-after children and young people guideline has been published. The guideline aims to help these children and young people reach their full potential and have the same opportunities as their peers.
Clinicians should be aware of this guideline and implement any necessary changes to their practice.
CKS October 2021
During the month of October 2021, the following Clinical Knowledge Summaries were published or updated:
All the above topics have been reviewed and updated in line with NICE guidance with minor layout changes. The Candida – female genital topic has been updated to remove the terms ‘uncomplicated’ and ‘complicated’ as they are not recommended in the BASHH national guideline. The Immunizations - seasonal influenza topic has been updated to include the recommendation that children aged over 2 years with a history of severe anaphylaxis to egg who have previously required intensive care management in hospital can be offered the egg-free cell-based quadrivalent influenza vaccine (QIVc) as an alternative to referral to a specialist for immunisation in hospital. The Tiredness/fatigue in adult’s topic has been updated with new recommendations on blood tests, referral timescales and the range of supportive measures to consider in primary care.
Clinicians can use the updated and new information when reviewing patients.
The information in the Prescribing News section has been adapted from the Prescribing Advice for GPs blog
This section has been adapted from www.prescriber.org.uk
|
|
